Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Frequently asked questions
What sector does Boundless Bio Inc. Common Stock (BOLD) operate in?
Boundless Bio Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Boundless Bio Inc. Common Stock (BOLD) current stock price?
As of the latest data, Boundless Bio Inc. Common Stock stock price is $2.89, with a previous close of $2.83. Boundless Bio Inc. Common Stock gained $0.06 in the last trading session, representing a 2.12% increase.
What is Boundless Bio Inc. Common Stock (BOLD) current market capitalization?
Boundless Bio Inc. Common Stock market cap is approximately 65.74 million.
What is Boundless Bio Inc. Common Stock (BOLD) Earnings Per Share (EPS)?
The trailing EPS is -$2.92, and the forward EPS is -$0.98.
What is Boundless Bio Inc. Common Stock (BOLD) EBITDA?
Boundless Bio Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -19.21 million.
Does Boundless Bio Inc. Common Stock (BOLD) pay dividends?
No. Boundless Bio Inc. Common Stock does not pay a dividend.
What is Boundless Bio Inc. Common Stock (BOLD) beta (volatility) score?
Boundless Bio Inc. Common Stock has a beta of 0.383, indicating lower volatility than the overall market.
